Drugs.com - FDA MedWatch Alerts

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

Audience: Patient, Health Professional, OBGYN, Endocrinology September 12, 2024 -- The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If there are signs and...

Feb 9, 2025 - 21:44
 0
Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause
Audience: Patient, Health Professional, OBGYN, Endocrinology September 12, 2024 -- The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If there are signs and...
Read More

Tags:

Previous Article

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for...

Next Article

Bionpharma Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension...

Related Posts

Main Products, Inc. Issues Recall of Umary Acido Hialuronico, Suplemento Alimenticio Due to the Presence of Undeclared Drug Ingredients

Main Products, Inc. Issues Recall of Umary Acido Hialur...

Feb 9, 2025  0

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

FDA Clarifies Policies for Compounders as National GLP-...

Feb 9, 2025  0

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Drug Safety Communication: Ocaliva (obeticholic acid) -...

Feb 9, 2025  0